Companies › SOTIO Biotech
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SOT201 CAR-T cell therapy | – | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| SOT109 CDH17-directed antibody-drug conjugate with exatecan payload | CDH17 | Phase 1 | Colorectal Cancer (Locally Advanced or Metastatic) | Nov 2027 |
| BOXR1030 anti-GPC3 CAR-T cell therapy | GPC3 | Phase 1 | Hepatocellular Carcinoma | Dec 2042 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06163391 | SOT201 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07693751 | SOT109 | Phase 1 | Colorectal Cancer (Locally Advanced or Metastatic) | Oncology | Nov 2027 |
| NCT05120271 | BOXR1030 | Phase 1 | Hepatocellular Carcinoma | Oncology | Dec 2042 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.